Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Shield Therapeutics stock price, quote, forecast and news

STX.L
GB00BYV81293
A2AE98

Price

0.03
Today +/-
+0
Today %
+0 %
P

Shield Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Shield Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Shield Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Shield Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Shield Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Shield Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Shield Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Shield Therapeutics’s growth potential.

Shield Therapeutics Revenue, EBIT and net profit per share

DateShield Therapeutics RevenueShield Therapeutics EBITShield Therapeutics Net Income
2027e72.53 M undefined4.53 M undefined2.5 M undefined
2026e53.46 M undefined-3.48 M undefined-5.18 M undefined
2025e58.54 M undefined-4.82 M undefined-7.96 M undefined
2024e28.78 M undefined-15.18 M undefined-18.05 M undefined
202313.09 M undefined-31.33 M undefined-33.29 M undefined
20225.5 M undefined-31.65 M undefined-49.79 M undefined
20211.52 M undefined-20.29 M undefined-19.68 M undefined
202010.39 M undefined-2.15 M undefined-2.63 M undefined
2019719,000 undefined-9.04 M undefined-8.8 M undefined
201811.88 M undefined-5.16 M undefined-1.79 M undefined
2017637,000 undefined-20.95 M undefined-19.59 M undefined
2016304,000 undefined-12.29 M undefined-15.02 M undefined
20150 undefined-6.43 M undefined-23.63 M undefined
20140 undefined-3.39 M undefined-12.91 M undefined
20130 undefined-3.84 M undefined-4.19 M undefined
20120 undefined-3.61 M undefined-3.15 M undefined

Shield Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024e2025e2026e2027e
00000011010151328585372
----------90.00400.00160.00115.38107.14-8.6235.85
------100.00-90.00-40.0030.77----
00000011090240000
-3-3-3-6-12-20-5-9-2-20-31-31-15-4-34
-------45.45--20.00-2,000.00-620.00-238.46-53.57-6.90-5.665.56
-3-4-12-23-15-19-1-8-2-19-49-33-18-7-52
-33.33200.0091.67-34.7826.67-94.74700.00-75.00850.00157.89-32.65-45.45-61.11-28.57-140.00
31.8931.8931.8942.71107.16119.02123.33123.93127.8210.42233.19722.540000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Shield Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Shield Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201220132014201520162017201820192020202120222023
0.650.4800.7320.9813.39.784.142.9416.353.413.95
00000.020.050.2600.223.953.399.99
00.05001.030.481.711.150.440.781.131.23
00000.420.130.110.951.382.211.763.2
3.370.0301.510.931.040.570.160.261.732.52.9
4.020.5602.2323.381512.426.45.2325.0112.1731.26
1012017191382632410238673
000000000000
000000004379579350
0.320.4400.5128.9829.9630.9629.927.2736.2214.2116.86
000000000000
000000000000
0.330.4500.532929.9730.9729.9227.7437.5915.3817.54
4.35102.7652.3844.9743.3836.3232.9662.627.5548.8
0.370.3700.691.621.751.751.761.764.575.3715.01
2.392.390077.9688.3488.3488.3588.35167.42169.48198.76
-7.01-23.010-19.29-31.26-48.91-49.69-58.03-59.89-108.99-157.87-190.29
-702180-397332366953-7,656-10,442-8,452
000000000000
-4.32-20.030-18.6448.441.2140.4332.1530.2855.356.5415.03
0.30.4201.211.491.80.022.670.45.511.744.05
0.60.2802.292.471.932.731.441.752.199.988.77
0.080.0500.070.030.040.20.050.080.151.010.7
000000000000
4.8408.2600000.020.030.210.110.21
5.820.748.263.583.993.762.954.172.258.0612.8313.74
00.2000000007.2520.03
000000000000
1.87010.0917.9300000000
1.870.210.0917.930000007.2520.03
7.690.9418.3521.53.993.762.954.172.258.0620.0733.77
3.37-19.0918.352.8652.3844.9743.3836.3232.5363.4126.6248.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Shield Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Shield Therapeutics's financial health and stability.

Assets

Shield Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Shield Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Shield Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Shield Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20122013201420152016201720182019202020212022
-3-4-13-24-15-19-1-8-2-19-49
00001222222
00000000000
00010111-2-16
01101830-201018
00000000000
00000-1-1-1000
-2-3-3-4-10-160-4-1-18-21
0000-3-3-3-10-2-2
0000-2-3-3-10-2-2
00000000000
00000000000
00010000009
30033612000270
30243311000279
-----2.00------
00000000000
0-2-1020-7-3-5-19-12
-2.95-3.37-3.43-4.32-13.43-19.56-3.19-5.45-1.42-20.33-23.78
00000000000

Shield Therapeutics stock margins

The Shield Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shield Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shield Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Shield Therapeutics's sales revenue. A higher gross margin percentage indicates that the Shield Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Shield Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Shield Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Shield Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Shield Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Shield Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Shield Therapeutics Margin History

Shield Therapeutics Gross marginShield Therapeutics Profit marginShield Therapeutics EBIT marginShield Therapeutics Profit margin
2027e30.78 %6.25 %3.44 %
2026e30.78 %-6.5 %-9.69 %
2025e30.78 %-8.23 %-13.6 %
2024e30.78 %-52.75 %-62.73 %
202330.78 %-239.44 %-254.44 %
202244.7 %-575.49 %-905.42 %
202135.48 %-1,336.01 %-1,295.46 %
202086.96 %-20.74 %-25.32 %
201932.55 %-1,256.61 %-1,223.92 %
201897.38 %-43.42 %-15.08 %
201775.67 %-3,289.01 %-3,075.04 %
201667.11 %-4,043.75 %-4,939.47 %
201530.78 %0 %0 %
201430.78 %0 %0 %
201330.78 %0 %0 %
201230.78 %0 %0 %

Shield Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Shield Therapeutics earnings per share therefore indicates how much revenue Shield Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Shield Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shield Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shield Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shield Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Shield Therapeutics Revenue, EBIT and net profit per share

DateShield Therapeutics Sales per ShareShield Therapeutics EBIT per shareShield Therapeutics Earnings per Share
2027e0.09 undefined0 undefined0 undefined
2026e0.07 undefined0 undefined-0.01 undefined
2025e0.07 undefined0 undefined-0.01 undefined
2024e0.04 undefined0 undefined-0.02 undefined
20230.02 undefined-0.04 undefined-0.05 undefined
20220.02 undefined-0.14 undefined-0.21 undefined
20210.01 undefined-0.1 undefined-0.09 undefined
20200.08 undefined-0.02 undefined-0.02 undefined
20190.01 undefined-0.07 undefined-0.07 undefined
20180.1 undefined-0.04 undefined-0.01 undefined
20170.01 undefined-0.18 undefined-0.16 undefined
20160 undefined-0.11 undefined-0.14 undefined
20150 undefined-0.15 undefined-0.55 undefined
20140 undefined-0.11 undefined-0.4 undefined
20130 undefined-0.12 undefined-0.13 undefined
20120 undefined-0.11 undefined-0.1 undefined

Shield Therapeutics business model

The company Shield Therapeutics PLC is a renowned British pharmaceutical conglomerate, founded in 2008. Based in Gateshead, England, Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. The company also has a strong presence in Europe and Asia. Shield Therapeutics' business model is to provide high-quality and innovative medical solutions to improve people's health and well-being. The company continuously researches new products to better cater to the needs of patients and doctors. The focus of Shield Therapeutics is on combating iron deficiency anemia, a severe blood disorder caused by a lack of iron in the body. Iron deficiency can be attributed to various factors, such as inadequate food intake, blood loss, or iron deficiency accumulation due to diseases. This anemia can lead to a range of symptoms, including fatigue, weak muscles, and dizziness. Long-term consequences can include life-threatening complications such as heart failure and strokes. Shield Therapeutics offers various products that can be used to treat iron deficiency anemia, such as Feraccru (in injection form) and Accrufer / Accrufer Tablets (in tablet form). Feraccru is an orally absorbed iron preparation indicated for the treatment of anemia in adults with iron deficiency anemia. Accrufer / Accrufer Tablets is an iron salt complex that is rapidly absorbed and shows high efficacy. The company also has its own research and development department, which focuses on researching innovative therapies and treatment methods. Shield Therapeutics actively participates in clinical research and the development of new therapeutic options aimed at improving the quality of life for people with iron deficiency anemia. More recently, Shield Therapeutics has also ventured into other disease areas. The company has developed clinical studies in collaboration with a top 10 pharmaceutical company to modify atherosclerosis through iron chelators. This is a groundbreaking research field that aims to develop advanced therapies for the treatment of infertility and chronic obstructive pulmonary disease (COPD). Overall, Shield Therapeutics has experienced strong growth in recent years and has solidified its position as a leading provider of pharmaceutical products for the treatment of iron deficiency anemia. The company has developed a wide range of products and can rely on a strong research and development department that constantly faces new challenges and offers innovative solutions for a variety of health issues. If Shield Therapeutics continues to be successful, it will undoubtedly continue to play a significant role in the industry. Answer: The company Shield Therapeutics specializes in the development and marketing of pharmaceutical products, with a particular focus on iron deficiency anemia. Shield Therapeutics is one of the most popular companies on Eulerpool.com.

Shield Therapeutics SWOT Analysis

Strengths

  • Strong product portfolio with a focus on innovative therapies.
  • Well-established brand and reputation in the pharmaceutical industry.
  • Ability to attract and retain top talent due to strong company culture and competitive compensation packages.

Weaknesses

  • Relatively small market share compared to larger competitors.
  • Limited financial resources for extensive marketing campaigns and research & development.
  • Dependence on a few key suppliers for raw materials.

Opportunities

  • Growing demand for innovative therapies in the pharmaceutical industry.
  • Expansion into new geographical markets with untapped potential.
  • Strategic partnerships and collaborations to enhance research capabilities and market reach.

Threats

  • Intense competition from larger pharmaceutical companies with greater resources.
  • Strict regulatory environment and potential challenges in gaining market approvals.
  • Economic downturns and fluctuations in exchange rates impacting overall business operations.

Shield Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Shield Therapeutics shares outstanding

The number of shares was Shield Therapeutics in 2023 — This indicates how many shares 722.544 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Shield Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Shield Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Shield Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Shield Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Shield Therapeutics.

Shield Therapeutics list of shareholders

%
Name
Stocks
Change
Date
7.16 % W. Health L.P.56,008,54105/17/2023
4.36 % Jupiter Asset Management Ltd.34,127,697-3,019,2957/21/2023
37.16 % AOP Orphan International AG290,584,7135,147,7546/14/2023
3.84 % Premier Asset Management Ltd30,000,00005/5/2023
1.71 % Fidelity International13,362,8953,446,7085/4/2023
1.65 % Dowgate Capital Limited12,920,42112,920,4215/18/2023
1.53 % Coutts & Co.11,982,76110,556,7403/21/2023
1.49 % Schweiger (Christian)11,651,71306/15/2023
1.36 % Killik & Co10,617,50310,617,5035/5/2023
1.09 % Albemarle Life Sciences LLP8,554,0338,554,0335/19/2023
1
2
3
4
5
...
10

Shield Therapeutics Executives and Management Board

Mr. Gregory Madison55
Shield Therapeutics Chief Executive Officer, Executive Director (since 2021)
Compensation 678,000
Mr. Hans Hasler67
Shield Therapeutics Non-Executive Chairman of the Board
Compensation 103,000
Mr. Anders Lundstrom61
Shield Therapeutics Non-Executive Independent Director
Compensation 51,000
Dr. Christian Schweiger
Shield Therapeutics Non-Executive Director
Compensation 45,000
Ms. Fabiana Lacerca-Allen50
Shield Therapeutics Non-Executive Independent Director
Compensation 45,000
1
2
3

Shield Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Beijing Aosaikang Pharma A Stock
Beijing Aosaikang Pharma A
SupplierCustomer0,32-0,290,850,670,79-
Jupiter Fund Management Stock
Jupiter Fund Management
SupplierCustomer-0,230,740,790,890,92-0,04
KOREA PHARMA Stock
KOREA PHARMA
SupplierCustomer-0,410,840,03-0,61--
Perrigo Stock
Perrigo
SupplierCustomer-0,70-0,650,260,650,750,69
1

Most common questions regarding Shield Therapeutics

What values and corporate philosophy does Shield Therapeutics represent?

Shield Therapeutics PLC represents values of innovation, integrity, and patient-centricity. With a strong focus on developing and commercializing pharmaceutical products, Shield Therapeutics is driven by the goal of addressing unmet medical needs for patients worldwide. The company is dedicated to delivering high-quality, evidence-based treatments that improve patients' lives. By promoting a culture of transparency, collaboration, and ethical conduct, Shield Therapeutics ensures that its stakeholders are at the heart of every decision and action. With a commitment to advancing healthcare solutions, Shield Therapeutics PLC strives to make a positive impact on the well-being of individuals and communities.

In which countries and regions is Shield Therapeutics primarily present?

Shield Therapeutics PLC is primarily present in various countries and regions around the world. The company has a global presence and operates in multiple countries including the United Kingdom, Germany, France, Spain, Italy, and the United States. Shield Therapeutics PLC has established a strong international presence to expand its reach and cater to a diverse range of markets. With its extensive geographical coverage, Shield Therapeutics PLC is well-positioned to leverage opportunities and serve patients’ needs in different parts of the world.

What significant milestones has the company Shield Therapeutics achieved?

Shield Therapeutics PLC has achieved significant milestones in its journey. The company successfully completed the pivotal Phase 3 clinical trials for its lead product, Feraccru®, a novel oral iron therapy for the treatment of iron deficiency anemia. Shield Therapeutics PLC received regulatory approval from the European Medicines Agency (EMA) for Feraccru® in 2016, allowing for its commercialization in Europe. The company also secured marketing authorizations in various European countries, including the UK, Germany, and Switzerland. These achievements highlight Shield Therapeutics PLC's commitment to addressing unmet medical needs and advancing innovative therapies in the field of iron deficiency anemia.

What is the history and background of the company Shield Therapeutics?

Shield Therapeutics PLC is a pharmaceutical company based in the United Kingdom. Founded in 2008, Shield Therapeutics focuses on the development and commercialization of products for the treatment of iron deficiency. The company is dedicated to addressing the unmet medical needs of patients suffering from iron deficiency-related conditions. Shield Therapeutics PLC aims to improve patient outcomes through its innovative and patient-centric approach to developing and delivering iron-based therapies. With a strong focus on research and development, Shield Therapeutics PLC is committed to advancing the field of iron deficiency treatment and improving the lives of patients worldwide.

Who are the main competitors of Shield Therapeutics in the market?

The main competitors of Shield Therapeutics PLC in the market include pharmaceutical companies focusing on the development and commercialization of iron deficiency treatments. Some prominent competitors in this space are Ferrexpo PLC, AMAG Pharmaceuticals, Inc., and Vifor Pharma Ltd. These companies also aim to address iron deficiency conditions through innovative medical solutions and therapies. Shield Therapeutics PLC competes with these industry players to establish its presence and provide effective treatment options for patients affected by iron deficiency.

In which industries is Shield Therapeutics primarily active?

Shield Therapeutics PLC is primarily active in the pharmaceutical industry.

What is the business model of Shield Therapeutics?

The business model of Shield Therapeutics PLC is focused on the development and commercialization of pharmaceutical products, particularly in the field of iron deficiency. Shield Therapeutics aims to offer innovative solutions to patients with iron deficiency, including those with chronic kidney disease. By focusing on this niche market, Shield Therapeutics strives to provide effective treatments and improve the quality of life for patients suffering from iron deficiency. Shield Therapeutics PLC is committed to research and development, ensuring the safety, efficacy, and accessibility of their pharmaceutical products.

What is the P/E ratio of Shield Therapeutics 2024?

The Shield Therapeutics P/E ratio is -1.06.

What is the P/S ratio of Shield Therapeutics 2024?

The Shield Therapeutics P/S ratio is 0.67.

What is the AlleAktien quality score of Shield Therapeutics?

The AlleAktien quality score for Shield Therapeutics is 6/10.

What is the revenue of Shield Therapeutics 2024?

The expected Shield Therapeutics revenue is 28.78 M GBP.

How high is the profit of Shield Therapeutics 2024?

The expected Shield Therapeutics profit is -18.05 M GBP.

What is the business model of Shield Therapeutics

Shield Therapeutics PLC is a British pharmaceutical company focused on the development and marketing of innovative drugs. The company specializes in the treatment of iron-deficiency anemia, which affects millions of people worldwide. The main focus of the company is the development of drugs for the treatment of iron-deficiency anemia in adults. They use a proprietary iron-based complex molecule called Ferric Maltol, which is able to transport and store iron more effectively and tolerably in the body compared to conventional iron supplements. The company's main product is Accrufer, an orally administered ferric iron supplement approved for the treatment of iron-deficiency anemia in adults. Accrufer has already proven to be effective and well tolerated in clinical studies and is now available on the market in several European countries, including Germany, the United Kingdom, Italy, and Spain. In addition to the development and marketing of Accrufer, Shield Therapeutics PLC also conducts research and development in the field of iron-based drugs. They collaborate closely with leading scientific institutions and research facilities to identify and develop new active substances. Furthermore, Shield Therapeutics PLC is involved in licensing and partnerships. The company aims to distribute its products worldwide and therefore works with various distribution partners and licensees to strengthen its global presence. Overall, the business model of Shield Therapeutics PLC is focused on providing effective and well-tolerated treatment for patients with iron-deficiency anemia. They pursue a holistic approach that includes research and development of new active substances as well as marketing and partnerships with other companies.

What is the Shield Therapeutics dividend?

Shield Therapeutics pays a dividend of 0 GBP distributed over payouts per year.

How often does Shield Therapeutics pay dividends?

The dividend cannot currently be calculated for Shield Therapeutics or the company does not pay out a dividend.

What is the Shield Therapeutics ISIN?

The ISIN of Shield Therapeutics is GB00BYV81293.

What is the Shield Therapeutics WKN?

The WKN of Shield Therapeutics is A2AE98.

What is the Shield Therapeutics ticker?

The ticker of Shield Therapeutics is STX.L.

How much dividend does Shield Therapeutics pay?

Over the past 12 months, Shield Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Shield Therapeutics is expected to pay a dividend of 0 GBP.

What is the dividend yield of Shield Therapeutics?

The current dividend yield of Shield Therapeutics is .

When does Shield Therapeutics pay dividends?

Shield Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Shield Therapeutics?

Shield Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Shield Therapeutics?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Shield Therapeutics located?

Shield Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Shield Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Shield Therapeutics from 8/3/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 8/3/2024.

When did Shield Therapeutics pay the last dividend?

The last dividend was paid out on 8/3/2024.

What was the dividend of Shield Therapeutics in the year 2023?

In the year 2023, Shield Therapeutics distributed 0 GBP as dividends.

In which currency does Shield Therapeutics pay out the dividend?

The dividends of Shield Therapeutics are distributed in GBP.

All fundamentals about Shield Therapeutics

Our stock analysis for Shield Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Shield Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.